SCHEMBL311730

SCHEMBL311730

O=c1cc(-c2ccc(O)nc2)oc2cc(O)ccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.71
HPGD P15428 5/20 0.71
SMN1; SMN2 Q16637 4/20 0.71
QPCT Q16769 3/20 0.71
ALDH1A1 P00352 3/20 0.71
KDM4E B2RXH2 3/20 0.71
CYP19A1 P11511 2/20 0.71
MAOA P21397 2/20 0.71
MAOB P27338 2/20 0.71
IP6K2 Q9UHH9 2/20 0.71
HSD17B10 Q99714 2/20 0.71
MPO P05164 1/20 0.71
MAPK1 P28482 1/20 0.71
TNKS O95271 4/20 0.64
TNKS2 Q9H2K2 3/20 0.64
PARP1 P09874 2/20 0.64
LCK P06239 2/20 0.64
ALOX5 P09917 1/20 0.64
POLH Q9Y253 1/20 0.64
CA12 O43570 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314217 0.89 MAPT (0.71) CYP3A4HPGDSMN1; SMN2QPCTALDH1A1
SCHEMBL5268977 0.85 HPGD (0.52) CYP3A4HPGDSMN1; SMN2QPCTALDH1A1
SCHEMBL311199 0.84 TNKS (0.67) CYP3A4HPGDSMN1; SMN2ALDH1A1KDM4E
SCHEMBL157723 0.84 CYP3A4 (1.00) CYP3A4HPGDSMN1; SMN2QPCTALDH1A1
SCHEMBL31167385 0.84 CYP3A4 (1.00) CYP3A4HPGDSMN1; SMN2QPCTALDH1A1
SCHEMBL312368 0.80 CYP3A4 (0.66) CYP3A4HPGDSMN1; SMN2QPCTALDH1A1
SCHEMBL12829685 0.79 CYP3A4 (0.79) CYP3A4HPGDSMN1; SMN2QPCTALDH1A1
SCHEMBL23804650 0.78 MAOB (0.82) CYP3A4HPGDSMN1; SMN2QPCTALDH1A1
SCHEMBL10812249 0.78 CYP3A4 (0.82) CYP3A4HPGDSMN1; SMN2QPCTALDH1A1
SCHEMBL29678122 0.78 TNKS (1.00) CYP3A4HPGDSMN1; SMN2QPCTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 CYP3A4 1730/4885HPGD 138/4885SMN1; SMN2 2736/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 CYP3A4 1730/4885HPGD 138/4885SMN1; SMN2 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.